ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015

Its studies are mostly in Carcinoma, Ovarian Epithelial, led by Medigene.

Furthest: phase 1, since Dec 12, 20241 company-led study, 1 open or runningNext primary completion: Dec 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Medigene11 open or runningphase 1since Dec 12, 2024Dec 12, 2024Dec 1, 2027phase 1 · NCT06748872

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2024First study: phase 1 study in Carcinoma, Ovarian EpithelialFirst studyNCT06748872 · 55 planned · United States

Ahead

  1. Dec 1, 2027Primary completion: phase 1 study in Carcinoma, Ovarian EpithelialNCT06748872

TargetBeta

“A preparation of autologous T-lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), and a progra”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06748872Carcinoma, Ovarian Epithelial · United States1Not yet recruitingDec 1, 202755

How it is read

Names in the registry

  • “TCR-T cells (MDG1015)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.